Metrics to compare | SCTX | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipSCTXPeersSector | |
|---|---|---|---|---|
P/E Ratio | −10.7x | −5.9x | −0.3x | |
PEG Ratio | - | −0.09 | 0.00 | |
Price/Book | −2.4x | 3.5x | 2.6x | |
Price / LTM Sales | 10.5x | 11.4x | 2.9x | |
Upside (Analyst Target) | - | 404.2% | 57.8% | |
Fair Value Upside | Unlock | 7.5% | 9.5% | Unlock |
Scribe Therapeutics Inc. is a clinical-stage biotechnology company, focuses on research and developing genetic medicines using CRISPR-based tools to address the root cause of diseases, with a primary focus on cardiometabolic conditions in the United States. The company offers STX-1150 designed to be a single-course in vivo epigenetic silencing treatment targeting the PCSK9 gene; STX-1200 is CRISPR-based gene editing program that aims to offer a permanent solution for patients with elevated Lp(a); and STX-1400 is designed to target and remove the transcriptional start site of the APOC3 gene and strongly reduce mRNA expression. It uses CRISPR-based platforms, such as ELXR, designed for precise, durable epigenetic silencing of genes without changing the underlying DNA sequence; and XE, designed to support specific and efficient gene editing. The company was incorporated in 2017 and is headquartered in Alameda, California.